MYGN
MYRIAD GENETICS INC
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeMyriad Genetics reported a major Q2 2026 earnings miss (EPS -$0.25 vs. -$0.06 estimate; revenue $190.7M vs. $210M estimate) with 11% YoY revenue decline, triggering a $90M downward guidance revision and EBITDA guidance suspension. The company faces significant headwinds from elevated payer friction ($11M prior-period collection loss, $4M receivables write-off), 16% prenatal revenue decline, and 15% ARPT compression in cancer testing, compounded by CFO separation and a pending securities investigation.
Red flags
- •Missed Q2 earnings by $0.19 per share (217% miss on bottom line)
- •Revenue missed by $19.4M (~9% below consensus)
- •Full-year 2026 revenue guidance cut by $90M midpoint
- •Adjusted EBITDA guidance suspended due to uncertainty
- •11% YoY revenue decline in Q2 2026
- •Prenatal health revenue declined 16% YoY
- •Average revenue per test declined 15% YoY in cancer care continuum
- •Elevated payer friction with higher denial rates and prior authorization delays
- •$4M aged receivables write-off
- •CFO separation agreement finalized
- •Securities investigation pending regarding potentially materially false or misleading statements
- •Stock down 29% on earnings, cumulative declines to -45.7% over subsequent days
- •TD Cowen price target cut from $6 to $4
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Glenview Capital | SC 13G/A | — | 0.0% | +8.0% vs SPY +6.3% abs | 2026-08-14 | ↗ |
| Glenview Capital | SC 13G | NEW | 5.3% | — | 2026-01-13 | ↗ |
Tracked Funds Holding (1)
| Fund | Manager | Shares Held | Position Value |
|---|---|---|---|
| Point72 | Steve Cohen | 239K | $1M |
Quarter-end 13F positions for the tracked funds holding this stock.